Status:

UNKNOWN

Intervention Study of Drugs in Patients Osteopenia and Osteoporosis

Lead Sponsor:

Chinese PLA General Hospital

Collaborating Sponsors:

Beijing Jishuitan Hospital

Beijing Aerospace General Hospital

Conditions:

Osteoporosis

Osteopenia, Osteoporosis

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

This is a 12 months, randomized, multicenter, open-label, parallel-group study in postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China to evaluate the efficacy a...

Detailed Description

This is a 12 months,randomized, multicenter, open-label, pragmatic-group study in postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China to evaluate the efficacy a...

Eligibility Criteria

Inclusion

  • Informed consent obtained before any trial-related activities
  • Postmenopausal women and male aged 50 years or old
  • Osteoporosis by DXA or fragility fracture history
  • Osteopenia with more than one osteoporotic risk factors

Exclusion

  • Secondary osteoporosis
  • Renal insufficiency (Ccr\< 35ml/min)
  • New fractures \< 3 months, prior bilateral hip fractures or surgical replacement.
  • Other medication contraindications
  • Malignant tumors
  • Mobility-impaired individuals

Key Trial Info

Start Date :

March 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2023

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT04719572

Start Date

March 1 2021

End Date

January 1 2023

Last Update

January 25 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PLA General Hospital

Beijing, Beijing Municipality, China, 100853